Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
Top Page
EyePoint Pharmaceuticals
(NASDAQ:EYPT)
Select Model
Select Model
Rating:54Neutral
Price Target:
$14.00
▲(1.52% Upside)
Action:ReiteratedDate:03/06/26
EYPT scores as mixed: strong clinical/program momentum and stated runway into 2027 support the outlook, but the financial profile is a major constraint with sharply widening losses, structural near-term revenue weakness, and heavy cash burn. Technicals are broadly neutral and valuation support is limited due to negative earnings.
Positive Factors
Phase 3 program momentum
Dosing of pivotal DME trials and an already-enrolling wet AMD Phase 3 program materially de-risks development timing. Clear mid-2026 and 2027 readout targets and global site networks improve visibility into regulatory milestones and potential commercialization windows, a durable catalyst for strategic planning.
Differentiated multi-mechanistic asset and Phase 2 efficacy
Multi-mechanistic inhibition with demonstrated early vision separation and durable single-dose effects provides a structural competitive edge versus single-mechanism anti-VEGFs. Potential for fewer injections and meaningful treatment-burden endpoints supports lasting commercial differentiation and payer/value narratives if Phase 3 confirms results.
Manufacturing, commercial readiness and near-term funding
An on-line cGMP facility and commercial hires indicate tangible manufacturing and go-to-market preparedness, reducing supply and launch execution risk. Combined with a $306M cash position and explicit runway into 2027, management can fund pivotal readouts, CMC/NDA work, and initial commercial build without immediate dilution, supporting near-term execution.
Negative Factors
Heavy cash burn and negative free cash flow
Sustained, large negative free cash flow (≈-$243M in 2025) indicates ongoing external funding needs. Persistent burn constrains strategic flexibility, raises dilution and financing risk beyond the stated 2027 runway, and forces prioritization of programs, which can slow commercialization or require partnering/licensing decisions.
Widening losses and rising operating expenses
Rapid OpEx expansion and a materially larger net loss reflect Phase 3 scale-up and higher fixed costs that will pressure margins until commercial revenues ramp. Large negative earnings undermine returns on equity and increase dependence on successful clinical outcomes to justify continued investment and absorb operating overhead.
Declining product revenue and reliance on deferred/license revenue
Sharp quarterly and annual revenue declines—partly driven by recognition timing of license-related revenue—reveal a weak commercial revenue base. Limited recurring product sales increase dependence on milestone/license payments and clinical success to generate sustainable revenue, heightening operational and financing risk if launches are delayed or uptake is slow.
EyePoint Pharmaceuticals (EYPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.15B
Dividend YieldN/A
Average Volume (3M)1.69M
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue Growth-7.38%
EPS Growth-49.03%
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.81
Shares Outstanding83,431,950
10 Day Avg. Volume1,528,055
30 Day Avg. Volume1,689,638
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.37
Price to Sales (P/S)42.66
P/FCF Ratio-5.50
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue34.09
Enterprise Value/Gross Profit36.49
Enterprise Value/Ebitda-4.46
Forecast
1Y Price Target
$36.60Price Target Upside165.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.22
Revenue Forecast (FY)$3.79M
EyePoint Pharmaceuticals Business Overview & Revenue Model
Company DescriptionEyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
How the Company Makes MoneyEyePoint makes money primarily by commercializing ophthalmic products and by generating revenue from collaborations related to its drug delivery and product development activities. Product revenue is driven by sales of its marketed ophthalmic therapy(s) to customers in the eye-care/retina treatment channel. The company also earns collaboration-related revenue when it enters into agreements with other pharmaceutical or biotechnology companies—typically through payments such as upfront fees, research or development funding, milestone payments tied to technical or regulatory progress, and/or royalties or profit-sharing on partnered products if they reach commercialization. Any additional revenue may come from licensing its technology or intellectual property to partners, where payments can similarly include upfront consideration, milestones, and ongoing royalties. null
EyePoint Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue Breakdown
Analyzes the sources of the company's revenue, highlighting key products or services that drive sales and indicating areas of growth or dependency.
Analyzes the sources of the company's revenue, highlighting key products or services that drive sales and indicating areas of growth or dependency.
Data provided by:
The Fly
The FlyEyePoint Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call presents a constructive clinical and commercial story centered on rapid Phase 3 progress (wet AMD readouts mid-2026, DME pivotal dosing underway), a differentiated multi-mechanistic asset with promising Phase 2 efficacy and a clean safety profile in ~190 patients, along with manufacturing and commercial hires to support a potential launch. Offsetting these positives are material financial headwinds from sharply lower quarter and year revenues, substantially higher operating expenses and an increased net loss, with cash down year-over-year though raised financing provides runway into 2027. Regulatory/commercial execution and continued safety monitoring remain key near-term risks. Overall, the positive clinical momentum and adequate near-term funding tip the balance toward a favorable outlook despite clear financial burn and execution risks.Q4-2025 Updates
Positive Updates
Advancing DuraVu into Phase 3 across key indications
Pivotal programs progressing: two Phase 3 wet AMD trials (Lugano and LUCIA) ongoing with top-line data expected beginning mid-2026; first patients dosed last week in both pivotal Phase 3 DME trials (COMO and CAPRI) with top-line DME data anticipated in 2027.
Strong Phase 2 efficacy signals and differentiated MOA
Phase 2 data (VERONA, DAVIO-2) showed durable single-dose efficacy, early separation vs aflibercept (as early as week 4: ~4–5 letters better and ~40 microns drier in VERONA), and potential six-month redosing. DuraVu's multi-mechanistic profile inhibits VEGF, PDGF and IL-6 via JAK1 (no Tie2 inhibition), supporting claims of faster onset and potential improved long-term outcomes.
Favorable safety profile across clinical program
No ocular or systemic SAEs attributed to DuraVu across >190 (191) treated patients in one Phase 1 and three Phase 2 trials; overall cataract incidence 5.8% (DAVIO-2 treatment arm ~8% vs EYLEA ~9%), vitreous floaters 5.2%, vitreous opacity ~1% in DAVIO-2, and only two mild cases of iritis (~1%) that resolved with topical therapy.
Commercial and manufacturing readiness
Commercial leadership strengthened with hire of experienced CCO Michael Campbell; 41,000 sq ft cGMP manufacturing facility in Northbridge, MA online >1 year with ~60 full-time employees supporting CMC submission and commercial supply and preparing for pre-approval inspection.
Robust global clinical infrastructure and investigator support
DME programs planned as global studies with ~140 sites across COMO and CAPRI, leveraging the wet AMD network; all invited wet AMD sites agreed to participate in DME studies, indicating investigator confidence and expected rapid enrollment.
Solid near-term capital position to fund operations
Cash and investments of $306 million as of 12/31/2025 (following a $173 million follow-on financing in October 2025) expected to fund operations into 2027 and fully support Phase 3 wet AMD NDA preparation and pivotal DME programs.
Statistically powered trial design with meaningful treatment-burden endpoint
Wet AMD trials use on-label aflibercept controls and noninferiority design; treatment-burden secondary endpoint measured after loading dose (DuraVu mandated 2 injections vs aflibercept 5 in year 1 = theoretical 60% reduction; applying DAVIO-2 supplementation rates implies ~40% reduction). Study is powered to detect treatment-burden differences as small as ~7–10%.
Negative Updates
Sharp quarter-over-quarter revenue decline
Q4 net revenue of $0.6 million vs $11.6 million in Q4 2024, a decrease of approximately 95%, driven primarily by recognition of remaining deferred revenue tied to the YUTIQ license agreement.
Full-year revenue contraction
Total net revenue for FY2025 was $31 million vs $43 million in FY2024, a decrease of ~28%, again primarily due to deferred revenue recognition related to the company's 2023 YUTIQ license transaction.
Rising operating expenses and increased net loss
Operating expenses increased materially as Phase 3 activity ramped: Q4 operating expenses rose to $71 million from $57 million (+~25%), and full-year operating expenses rose to $275 million from $189 million (+~46%), driven primarily by Phase 3 development. Net loss widened to $232 million for FY2025 vs $131 million in FY2024 (+~77%).
Higher cash burn and declining cash balance
Cash and investments declined from $371 million at 12/31/2024 to $306 million at 12/31/2025 (a decrease of ~17.5%), highlighting increased cash burn related to Phase 3 expenditures despite the October 2025 $173 million financing.
Regulatory and competitive uncertainties remain
FDA expectations around single-study approvals create ambiguity (single-trial filing unlikely for common diseases like wet AMD/DME); competitive sustained-release programs and potential marketplace entrants could impact launch dynamics and uptake; reimbursement/step-therapy considerations could affect access, though company is proactively preparing payer workstreams.
Clinical risks remain despite favorable profile
Although inflammation and other adverse events have been low to date, the broader class of investigational agents has seen inflammatory signals in other trials; continued DMC and safety monitoring (next DMC meeting scheduled for May) will be important as Phase 3 enrollment and dosing progress.
Company Guidance
EyePoint’s guidance and milestones were detailed and metric‑rich: top‑line Phase 3 wet AMD data from Lugano (with LUCIA closely following) is expected beginning mid‑2026 (next DMC safety review in May), and two pivotal DME Phase 3 trials (COMO and CAPRI) have begun randomization with first patients dosed last week, enrollment expected to complete in 2026 and top‑line DME data anticipated in 2027; cash and investments totaled $306M at 12/31/2025 (down from $371M a year earlier) after a $173M follow‑on in October, and management expects this to fund operations into 2027 and fully fund the DME program and NDA preparation for wet AMD; Q4 2025 revenue was $0.6M (Q4 2024: $11.6M) and FY revenue $31M (2024: $43M); Q4 OpEx $71M (vs $57M), FY OpEx $275M (vs $189M); Q4 net loss ~ $68M, $0.81/sh (vs $41M, $0.64), FY net loss $232M, $3.17/sh (vs $131M, $2.32); net non‑operating income was $3M in Q4 and $12M for the year; clinical metrics include >190 patients treated across four completed trials with no drug‑attributed ocular/systemic SAEs, cataracts of 5.8% in the 191‑patient database (DAVIO‑2 arms ~8%, aflibercept ~9%), floaters 5.2%, DAVIO‑2 unsupplemented treated eyes gained ~2.1 letters vs control, VERONA showed ~4–5 letter early separation and ~40 µm CST benefit at week 4, insert payload ~94% drug/6% matrix, vorolanib JAK1 IC50 ≈80 nM, ~140 global sites planned across the DME studies, Phase 3 dosing uses two inserts with an expected first‑year injection burden of two DuraVu vs five aflibercept (a theoretical 60% reduction if no supplementation; ~40% reduction using DAVIO‑2 supplementation rates), and a 41,000 sq ft cGMP facility with ~60 FTEs is online supporting CMC and commercial supply.EyePoint Pharmaceuticals Financial Statement Overview
Summary
Overall fundamentals are pressured by sharply widening losses (FY2025 net loss ~$232M vs ~$131M) and very heavy cash burn (FY2025 FCF about -$243M) alongside declining revenue (~-26% YoY). The main offset is a relatively solid balance sheet for a biotech, with low leverage (debt-to-equity ~0.07) and meaningful equity/cash to support ongoing development.Income Statement
Profitability remains weak: the company is generating consistently negative earnings, and losses expanded sharply in 2025 (net loss of ~$232M vs. ~$131M in 2024). Revenue also declined meaningfully in 2025 (down ~26% year over year) after being roughly flat to modestly positive in prior years. A key positive is very strong gross profitability (gross margin ~93% in 2025), but operating costs continue to overwhelm gross profit, driving very large negative operating and net margins.28
Negative
Balance Sheet
The balance sheet looks relatively solid for a biotech: leverage is low, with debt-to-equity around ~0.07 in 2025 and total debt of ~$21M against equity of ~$306M. Equity is substantial, which provides financial flexibility, but persistent losses are translating into weak returns on equity (negative in every year shown), and assets declined in 2025 versus 2024, signaling some balance-sheet burn over time.72
Positive
Cash Flow
Cash generation is a major concern: operating cash flow and free cash flow were deeply negative in 2025 (about -$240M and -$243M, respectively) and deteriorated materially versus 2024. Free cash flow has been negative in nearly all years shown (only 2023 was close, with slightly negative free cash flow), implying ongoing external funding needs. A modest positive is that cash burn is broadly consistent with reported losses (free cash flow roughly in line with net loss in 2024–2025), but the magnitude of the burn is the key risk.24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.37M | 43.27M | 46.02M | 41.40M | 36.94M |
| Gross Profit | 29.30M | 39.56M | 41.39M | 33.08M | 28.76M |
| EBITDA | -243.43M | -129.23M | -69.00M | -96.62M | -50.15M |
| Net Income | -231.96M | -130.87M | -70.80M | -102.25M | -58.42M |
Balance Sheet | |||||
| Total Assets | 364.00M | 418.46M | 355.18M | 180.36M | 263.37M |
| Cash, Cash Equivalents and Short-Term Investments | 306.09M | 370.91M | 331.05M | 144.56M | 211.56M |
| Total Debt | 20.77M | 21.86M | 4.91M | 46.35M | 39.20M |
| Total Liabilities | 57.88M | 81.96M | 88.86M | 83.99M | 78.99M |
| Stockholders Equity | 306.11M | 336.50M | 266.32M | 96.37M | 184.38M |
Cash Flow | |||||
| Free Cash Flow | -243.39M | -130.28M | -1.61M | -67.16M | -50.25M |
| Operating Cash Flow | -240.11M | -126.23M | 1.88M | -65.00M | -50.10M |
| Investing Cash Flow | 68.58M | -219.35M | -3.31M | -17.27M | -33.12M |
| Financing Cash Flow | 173.65M | 164.02M | 187.07M | -690.00K | 216.90M |
EyePoint Pharmaceuticals Technical Analysis
Negative
13.79
Price Trends
15.17
Negative
15.00
Negative
13.12
Positive
Market Momentum
-0.48
Positive
40.26
Neutral
23.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EYPT, the sentiment is Negative. The current price of 13.79 is below the 20-day moving average (MA) of 15.84, below the 50-day MA of 15.17, and above the 200-day MA of 13.12, indicating a neutral trend. The MACD of -0.48 indicates Positive momentum. The RSI at 40.26 is Neutral, neither overbought nor oversold. The STOCH value of 23.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EYPT.
EyePoint Pharmaceuticals Risk Analysis
EyePoint Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. EyePoint Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
EyePoint Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.96B | -273.00 | 12.06% | ― | 1128.17% | ― | |
57 Neutral | $1.08B | 440.65 | 0.87% | ― | 26.54% | ― | |
55 Neutral | $2.76B | -6.64 | -50.30% | ― | 53.28% | 21.77% | |
54 Neutral | $1.15B | -5.61 | -88.31% | ― | -7.38% | -49.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $905.00M | -7.34 | 170.21% | ― | 8.00% | -10.15% | |
47 Neutral | $591.61M | -3.30 | -1065.47% | ― | 96.83% | -61.92% |
* Healthcare Sector Average
EYPT
EyePoint Pharmaceuticals
13.79
7.69
126.07%
URGN
Urogen Pharma
18.59
6.57
54.66%
MGTX
Meiragtx Holdings
7.35
-0.30
-3.92%
STOK
Stoke Therapeutics
33.19
24.86
298.44%
TNGX
Tango Therapeutics
19.32
17.54
985.39%
PHAR
Pharming Group
15.47
6.69
76.10%
EyePoint Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
EyePoint Starts Global Phase 3 Trials for DURAVYU
Positive
Mar 2, 2026
On March 2, 2026, EyePoint announced that the first patients have been dosed in its global Phase 3 COMO and CAPRI clinical trials evaluating DURAVYU for diabetic macular edema, signaling the start of pivotal late-stage testing in a major retinal indication. These randomized, aflibercept-controlled non-inferiority studies, each targeting about 240 patients and using six‑month redosing, are designed to leverage positive Phase 2 VERONA data and prior regulatory alignment in the U.S. and Europe to demonstrate that DURAVYU can match standard-of-care vision outcomes while reducing treatment burden.
The launch of these DME trials, alongside an already fully enrolled Phase 3 program in wet AMD, underscores EyePoint’s bid to establish DURAVYU as a first- and best-in-class sustained-release tyrosine kinase inhibitor in the two largest retinal disease markets. Successful results, with topline DME data expected in the second half of 2027 and wet AMD data anticipated beginning in mid-2026, could materially strengthen the company’s competitive position in ophthalmology, offering patients a longer-acting, multi-mechanism alternative to existing anti-VEGF therapies and potentially reshaping treatment paradigms for vision‑threatening diabetic eye disease.
The most recent analyst rating on (EYPT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.